Haloperidol Depo Krka (Haloperidol)

Haloperidol Depo Krka is indicated for the treatment of several severe psychiatric disorders where long‑acting antipsychotic control is desired.

• Schizophrenia, including maintenance therapy for chronic cases.
• Acute psychotic episodes that require rapid stabilization.
• Manic episodes associated with bipolar disorder when oral therapy is insufficient.
• Adjunctive treatment for patients with treatment‑resistant psychosis.
• Situations where adherence to daily oral medication is a concern.

The safety profile of Haloperidol Depo Krka reflects its dopamine D2 antagonism and includes both frequent and rare reactions.

Common

• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Sedation or drowsiness.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or changes in appetite.

Serious

• Neuroleptic malignant syndrome, a potentially life‑threatening condition.
• Tardive dyskinesia with persistent involuntary movements.
• Severe hypotension or cardiac arrhythmias.
• Elevated prolactin leading to galactorrhea or menstrual disturbances.

Before initiating Haloperidol Depo Krka, clinicians should evaluate several patient‑specific factors to minimize risks.

• History of cardiovascular disease, including arrhythmias or prolonged QT interval.
• Prior episodes of extrapyramidal reactions or tardive dyskinesia.
• Current use of other central nervous system depressants or anticholinergic agents.
• Liver or renal impairment that may affect drug clearance.
• Pregnancy, lactation, or plans for conception, as safety data are limited.
• Elderly patients, especially those with dementia‑related psychosis, due to increased sensitivity.

Haloperidol Depo Krka can interact with a range of medications; awareness of these interactions helps avoid adverse effects.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics that may amplify extrapyramidal risk.
• Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol levels.

Use with caution

• CYP3A4 inducers like carbamazepine or rifampin, which may reduce efficacy.
• CNS depressants, including benzodiazepines and opioids, for additive sedation.
• Anticholinergic medications that may mask early signs of extrapyramidal symptoms.